Zymeworks Inc
NASDAQ:ZYME

Watchlist Manager
Zymeworks Inc Logo
Zymeworks Inc
NASDAQ:ZYME
Watchlist
Price: 14.3 USD 0.7% Market Closed
Market Cap: 989m USD
Have any thoughts about
Zymeworks Inc?
Write Note

Zymeworks Inc
Retained Earnings

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Zymeworks Inc
Retained Earnings Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Retained Earnings CAGR 3Y CAGR 5Y CAGR 10Y
Zymeworks Inc
NASDAQ:ZYME
Retained Earnings
-$797.8m
CAGR 3-Years
-7%
CAGR 5-Years
-30%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Retained Earnings
-$5B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Retained Earnings
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Retained Earnings
-$25.5B
CAGR 3-Years
-4%
CAGR 5-Years
-5%
CAGR 10-Years
-18%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Retained Earnings
$8.7B
CAGR 3-Years
53%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Retained Earnings
$30.8B
CAGR 3-Years
22%
CAGR 5-Years
36%
CAGR 10-Years
71%
No Stocks Found

Zymeworks Inc
Glance View

Market Cap
1B USD
Industry
Biotechnology

Zymeworks Inc. is a biopharmaceutical company. The company is headquartered in Middletown, Delaware and currently employs 286 full-time employees. The company went IPO on 2019-06-24. Its lead product candidate is zanidatamab, a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its product candidate ZW49, combines the design of zanidatamab with its ZymeLink ADC platform, comprised of its cytotoxin and cleavable linker. The firm operates through a number of platforms, including Azymetric, ZymeLink, EFECT and ProTECT. Its Azymetric is a bispecific platform that enables therapeutic antibodies to simultaneously bind multiple distinct locations on a target or to multiple targets. The Company’s ZymeLink is an antibody-drug conjugate (ADC) platform comprised of cytotoxins and the linker technology used to couple these cytotoxins to tumor-targeting antibodies or proteins.

ZYME Intrinsic Value
18.33 USD
Undervaluation 22%
Intrinsic Value
Price

See Also

What is Zymeworks Inc's Retained Earnings?
Retained Earnings
-797.8m USD

Based on the financial report for Sep 30, 2024, Zymeworks Inc's Retained Earnings amounts to -797.8m USD.

What is Zymeworks Inc's Retained Earnings growth rate?
Retained Earnings CAGR 5Y
-30%

Over the last year, the Retained Earnings growth was -20%. The average annual Retained Earnings growth rates for Zymeworks Inc have been -7% over the past three years , -30% over the past five years .

Back to Top